Chemoradiation for anal cancer
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Anal cancer is one of the clearest success stories in oncology. It used to be treated by removing the anus and rectum and creating a permanent colostomy. Chemoradiation replaced that for most people, with equal or better survival and the anatomy left intact.
Two things about it are commonly misunderstood: a genetic test that should happen before the chemotherapy starts, and how long you are supposed to wait before judging whether it worked.
Related pages: Anal cancer
The bottom line
- Concurrent chemoradiation is the standard treatment for most anal cancers.
- Tumours continue to shrink for months after radiation ends.
- Surgery is reserved for persistent or recurrent disease.
- DPYD gene variants cause severe, sometimes fatal, toxicity from fluorouracil.
- The best chemotherapy partner for radiation in older or less fit patients, where trials continue.
- Whether immunotherapy will have a role in earlier-stage disease.
The story, step by step
- 1. What it is ()
- 2. DPYD ()
- 3. Waiting ()
- 4. Salvage ()
What the evidence labels mean
Radiation and chemotherapy together
What happens
The regimen, in outline.
What the research shows
- Radiation is given daily on weekdays, usually over about 5 to 6 weeks, to the anus and the pelvic and groin lymph nodes.
- Modern delivery uses intensity-modulated radiotherapy, IMRT, which shapes the dose around the target and has substantially reduced skin, bowel and blood-count toxicity compared with older techniques.
- Chemotherapy runs at the same time, most often 5-fluorouracil with mitomycin. Capecitabine, a tablet form of the same family, is used in place of infused 5-FU in some protocols.
- The chemotherapy is given at doses that make the radiation work better rather than at doses intended to treat the cancer on their own.
- Mitomycin suppresses blood counts, so blood tests are frequent and a low count can delay a cycle.
- People with HIV are treated with the same approach, with attention to counts and interactions; outcomes with modern antiretroviral therapy are broadly comparable.
Why it matters
The anatomy-preserving part is the point: for most people this treatment ends with a functioning anus, which is what the alternative operation removes.
What's still uncertain
- The optimal chemotherapy partner for people who cannot tolerate mitomycin, which is an active question.
Read more
- National Cancer Institute: Anal cancer treatment (PDQ)Government
- MedlinePlus: Radiation therapyGovernment
- MedlinePlus: Anal cancerGovernment
Next: DPYD
The test that should come first
What happens
A safety step many patients have never heard of.
What the research shows
- The DPD enzyme breaks down fluorouracil and capecitabine. Around 6 percent of people carry a DPYD gene variant that reduces that activity, and a small number have almost none.
- In those people, standard doses can cause severe mucositis, diarrhoea, blood count collapse and, rarely, death.
- Testing is standard practice across Europe, the United Kingdom, Australia and much of Canada. The United States moved more slowly: the FDA added a boxed warning to capecitabine's label in late 2025 recommending DPYD testing before treatment, and updated the fluorouracil label in February 2026 to recommend the same.
- Historically, testing was done in well under 1 percent of United States patients starting these drugs, so being asked about it is still not guaranteed.
- Where a variant is found, the dose is reduced according to an established algorithm, or another approach is used. It does not mean treatment is off the table.
- Asking whether DPYD testing has been done before starting 5-FU or capecitabine is a reasonable question, and the answer is increasingly yes.
Why it matters
This is the single most actionable safety point in anal cancer treatment, and the practice around it changed very recently.
What's still uncertain
- How quickly universal testing will become routine in the United States, which is in flux.
Read more
- FDA: Fluorouracil and capecitabine labeling, DPYD testingGovernment
- MedlinePlus: Fluorouracil injectionGovernment
- National Cancer Institute: Anal cancer treatment (PDQ)Government
Next: Waiting
Why response is judged at six months
What happens
The most counterintuitive part of this treatment.
What the research shows
- Anal tumours continue to shrink for weeks and months after radiation finishes. A tumour still palpable at the end of treatment is expected, not a failure.
- Response is assessed at around 26 weeks, roughly six months, from the start of treatment. Many tumours that look incomplete at 11 weeks have resolved entirely by then.
- This matters because biopsying or operating too early leads to unnecessary permanent colostomies. The ACT II trial established the later assessment point for exactly this reason.
- Monitoring in the interval is by examination, which should show steady regression rather than growth.
- Growth, or new symptoms, at any point is assessed promptly. Slow residual shrinkage is not.
- The waiting is hard. Knowing that the schedule is deliberate, and that it exists to avoid removing an anus that did not need removing, helps some people.
Why it matters
If someone suggests surgery because a lump is still there a few weeks after treatment, the six-month assessment point is worth raising.
What's still uncertain
- The ideal assessment timing in individual cases, which is a judgement balanced against the risk of missing persistent disease.
Read more
- National Cancer Institute: Anal cancer treatment (PDQ)Government
- MedlinePlus: Anal cancerGovernment
- National Cancer Institute: Survivorship and late effectsGovernment
Next: Salvage
Surgery, if it is needed
What happens
What happens when chemoradiation does not clear it.
What the research shows
- Where disease persists at the six-month assessment, or recurs later, the operation is an abdominoperineal resection: removal of the anus, rectum and surrounding tissue, with a permanent colostomy.
- It is major surgery with a long recovery and a significant wound, and it is also potentially curative, which is why it is offered.
- A permanent stoma is a large change and is manageable. Stoma nurses exist precisely for this and should be met before surgery rather than after.
- A smaller number of people need a temporary stoma during chemoradiation itself, usually because the tumour is obstructing or causing a fistula.
- Metastatic disease, which is uncommon at diagnosis, is treated with chemotherapy and, increasingly, immunotherapy, which is a separate pathway from the one described here.
- Clinical trials are worth asking about, particularly for recurrent or metastatic disease, where options are developing.
Why it matters
Most people never need this, which is the achievement of the chemoradiation approach. It is listed because knowing the backstop exists is better than discovering it under pressure.
What's still uncertain
- The role of immunotherapy in persistent local disease, which is being studied.